QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients. First cleared in 2018 for professional and personal use by adults 18 years and older, PCA 500's new FDA clearance expands its indication for use to all pediatric populations, including: newborns, infants, children and adolescents.

專注研發心電圖（ECG）技術的美商宇心生醫，今(9/27)宣布成功完成1200萬美元（約3.8億台幣）的B輪籌資。這筆資金由中華開發貳生醫基金、台杉資本領投，將有助美商宇心生醫加速在全球市場拓展、研發製造、與長期戰略佈局方面的推進。

The facts are grim: One person dies from cardiovascular disease every 37 seconds in the United States. One of the most effective tests for the heart is the twelve-lead electrocardiogram (ECG).

Many fields of medicine are undergoing a transformation due to the COVID-19 pandemic, as patients are kept away from clinics as much as possible.

Las Vegas-- 01/11/2019 -- QT Medical announces the launch of its Personal Cardiac Assistant (PCA 500) at the world’s largest technology showcase, CES. PCA 500 is the only FDA-cleared, hospital quality 12-lead electrocardiogram (ECG) for personal use. QT Medical’s CEO Dr. Ruey-Kang Chang and his team exhibited the PCA 500 at the startup zone in Eureka Park.

宇心生醫QT Medical 誠摯邀請您蒞臨參觀 2021台灣醫療科技展

QT Medical strives to make hospital grade 12-lead electrocardiograms (ECG) accessible to everyone everywhere.

QT ECG is selected to be among 4 Finalists in the Life Science Research Tools and Medical Device Category